Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

Stock Information for Relmada Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.